Abstract
This chapter provides an overview of the proteome profiling technology and its potential benefits for identification and clinical assessment of progression of pathological conditions. The introduction of modern mass spectrometry (MS) strategies and tools—assessing data-dense putative markers associated with inflammatory or immune endpoints—has changed the world of biological investigation. SELDITOF (surface-enhanced laser desorption/ionization time-of-flight) technology is one of these increasingly popular tools, using “shooting” of protein mixtures with focused lasers, in the search for known and surrogate biomarkers for disease diagnosis and prognosis. SELDITOF-MS rapidly provides a protein expression profile from a variety of biological and clinical samples. The potential efficacy of this system for serum protein profiling of cancer in human breast, colon, head and neck, lung, ovarian, prostate cancer, and hepatoma has been recently demonstrated. Technical limitations that affect the interpretive analysis of the profiles are discussed. Some statistical methods used to decipher the profiles and their usage in diagnosing or predicting the condition of patients are described in brief. The potential of these methods in the task of differentiating between individuals with and without cancer is discussed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
